You are currently viewing Lilly to build $2.5 billion Germany plant as obesity drug demand soars

Lilly to build $2.5 billion Germany plant as obesity drug demand soars

[ad_1]

DealsHealth

Reuters exclusively reported that Eli Lilly (LLY.N) will build its first plant in Germany in the western town of Alzey for 2.3 billion euros ($2.5 billion), the U.S. drugmaker said on Friday, as the sector scrambles to meet soaring demand for new diabetes and obesity therapies. 

Market Impact

As the sector scrambles to meet demand for new diabetes and obesity therapies, the investment, confirmed by Lilly on Nov 17, will contribute to meeting surging demand for weight-loss drug Mounjaro from 2027. Eli Lilly and Danish rival Novo Nordisk (NOVOb.CO) are leading a race to seize an estimated $100 billion future global market for anti-obesity treatments.   

Article Tags

Topics of Interest: DealsHealth

Type: Reuters Best

Sectors: Pharmaceuticals & HealthcareRetail & Consumer Goods

Regions: Europe

Countries: Germany

Win Types: Exclusivity

Story Types: Exclusive / Scoop

Media Types: Text

Customer Impact: Important Regional Story

[ad_2]
Source link

Gadget Explorer Pro

Gadget Explorer Pro is an expert writer specializing in comprehensive reviews, insightful articles, and detailed comparisons of consumer electronics. With a passion for technology and years of experience, they offer unbiased analysis of the latest gadgets, from cameras to smart home devices. Known for making complex tech understandable, Gadget Explorer Pro helps readers make informed decisions. Follow them for expert advice and the latest trends in the world of technology.

Leave a Reply